Huntington National Bank Insmed Inc Transaction History

Huntington National Bank

$13.5 Billion
Q3 2024

A detailed history of Huntington National Bank transactions in Insmed Inc stock. As of the latest transaction made, Huntington National Bank holds 632 shares of INSM stock, worth $47,956. This represents 0.0% of its overall portfolio holdings.

Number of Shares

632

Previous 665 4.96%

Holding current value

$47,956

Previous $44,000 4.55%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 06, 2024	SELL	$62.0 - $79.01 $2,046 - $2,607	-33 Reduced 4.96%	632 $46,000
Q2 2024 Aug 08, 2024	SELL	$22.0 - $69.71 $15,532 - $49,215	-706 Reduced 51.5%	665 $44,000
Q1 2024 May 03, 2024	BUY	$25.72 - $29.94 $5,426 - $6,317	211 Added 18.19%	1,371 $37,000
Q4 2023 Feb 07, 2024	SELL	$23.42 - $31.74 $1,639 - $2,221	-70 Reduced 5.69%	1,160 $35,000
Q3 2023 Nov 08, 2023	BUY	$19.86 - $26.93 $4,349 - $5,897	219 Added 21.66%	1,230 $31,000
Q2 2023 Aug 11, 2023	BUY	$16.44 - $21.1 $1,939 - $2,489	118 Added 13.21%	1,011 $21,000
Q1 2023 May 10, 2023	BUY	$16.26 - $21.73 $4,292 - $5,736	264 Added 41.97%	893 $15,000
Q4 2022 Feb 09, 2023	BUY	$16.98 - $23.15 $186 - $254	11 Added 1.78%	629 $12,000
Q3 2022 Nov 07, 2022	SELL	$20.88 - $28.21 $83 - $112	-4 Reduced 0.64%	618 $13,000
Q2 2022 Aug 09, 2022	BUY	$17.07 - $25.71 $9,098 - $13,703	533 Added 598.88%	622 $12,000
Q4 2021 Jan 21, 2022	BUY	$25.89 - $33.45 $2,304 - $2,977	89 New	89 $2,000
Q1 2020 Apr 27, 2020	SELL	$13.63 - $33.98 $9,200 - $22,936	-675 Closed	0 $0
Q4 2019 Jan 17, 2020	BUY	$16.12 - $24.98 $10,881 - $16,861	675 New	675 $16,000

Others Institutions Holding INSM

# of Institutions

467

Shares Held

182M

Call Options Held

2.27M

Put Options Held

3.33M

View Full List

About INSMED Inc

Ticker INSM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 135,476,992
Market Cap $10.3B
Description
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversibl...

More about INSM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Huntington National Bank, based on Form 13F filings with the SEC.

News

Stay updated on Huntington National Bank with notifications on news.

Account

Huntington National Bank Insmed Inc Transaction History